- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05177120
Central Sensitization in Familial Mediterranean Fever (FMF) (FMF)
November 9, 2022 updated by: Marmara University
Central Sensitization in Familial Mediterranean Fever: A Cross-Sectional Observational Study
Familial Mediterranean Fever (FMF) is an autosomal recessive inherited disease with a course of autoinflammation, which is characterized by the episodes of fever and serositis.
Central sensitization (CS) is defined as increased response to normal or sub-threshold stimuli of central nervous system and its close relationship with many rheumatological diseases has been demonstrated in several studies.
However, there are no data on the frequency of CS in FMF patients.
Study Overview
Status
Completed
Intervention / Treatment
- Diagnostic test: Central Sensitization Inventory
- Other: Short form-36
- Other: Pittsburgh Sleep Quality Index
- Other: Health assessment questionnaire
- Other: Hospital anxiety and depression scale
- Diagnostic test: Fibromyalgia rapid screening tool
- Other: Familial Mediterranean Fever Quality of life scale
Detailed Description
Familial Mediterranean fever (FMF) is a self-limiting autoinflammatory disease with well-defined genetic and clinical features.
Recurrent episodes of fever and serositis accompanied by increased acute phase reactants and good response to colchicine are the core components of the disease.
The frequency of this disease, which is common in Eastern Mediterranean countries, is variable according to regions, but it is reported as 1/1000.
In the pathogenesis of the disease, the mutation of the MEFV (Mediterranean Fever) gene, which is located on the 16th chromosome and encodes the pyrin protein, is known as the basic mechanism.In rheumatic diseases, inflammatory mediators cause CS by first creating changes in the regulation of pain in peripheral neurons and then in spinal and supraspinal pathways.
Stimulation of peripheral nerves by mediators released during inflammation results in neurogenic inflammation, which is among the peripheral sensitization (PS) mechanisms.
PS is defined as the increased sensitivity of nociceptive neurons to normal or below-threshold stimuli and constitutes the first step in the development of CS.Similar to other autoimmune diseases, it is possible that the neuroinflammatory process triggers peripheral and central sensitization mechanisms in FMF patients and affects pain pathways.
Study Type
Observational
Enrollment (Actual)
100
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Sinop, Turkey, 57200
- Feyza Nur YUCEL
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 75 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
Patients with FMF
Description
Inclusion Criteria:
- Agree to participate in the study
Exclusion Criteria:
- Had another systemic inflammatory rheumatic diseases
- Using centrally acting pain medications (e.g., pregabalin, duloxetine, opioids) or glucocorticoids (>10 mg prednisone or its equivalent)
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Case-Only
- Time Perspectives: Cross-Sectional
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
FMF patients
Patients with diagnosed FMF
|
Standardized questionnaire to determine the level of central sensitization
Other Names:
Standardized questionnaire to investigate the quality of life in patients
Other Names:
Standardized questionnaire to investigate the sleep quality and disturbance
Other Names:
Standardized questionnaire used to detect the presence of disability
Other Names:
Standardized questionnaire to investigate the depression and anxiety
Other Names:
Standardized questionnaire to determine the presence of fibromyalgia
Other Names:
Standardized questionnaire to investigate the quality of life in Familial Mediterranean Fever patients
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Central Sensitization Inventory (CSI)
Time Frame: 6 months
|
25 somatic and psychosocial symptoms, which are frequently found in patients with central sensitization in part A, are questioned.
In part B, the presence of diseases whose relationship with central sensitization is well defined is questioned in the patient without participating in scoring.
Central sensitization is assumed in patients who score 40 or more over 100 points.
|
6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Short form-36 (SF-36)
Time Frame: 6 months
|
The 36-Item Short Form Survey (SF-36) is an oft-used, well-researched, self-reported measure of health.The scale consists of 36 questions questioning 8 sub-parameters regarding the health status of the person.These parameters are physical function, pain, limitation due to physical and emotional problems, emotional well-being, social function, fatigue and general health perception.
High scores are associated with improved quality of life.
|
6 months
|
Familial Mediterranean Fever Quality of Life Scale (FMF-QoL)
Time Frame: 6 months
|
FMF-QoL was developed to evaluate the quality of life in FMF patients.
This scale consists of 20 questions in the form of a Likert scale and the total scoring is between 0-80.
High scores indicate a decrease in quality of life.
|
6 months
|
Health Assessment Questionnaire (HAQ)
Time Frame: 6 months
|
n the scale, difficulty in performing 20 specific tasks from 8 categories is questioned and the scoring is between 0-60.
High scores are associated with increased disability.
|
6 months
|
Hospital Anxiety and Depression Scale (HADS)
Time Frame: 6 months
|
This scale consists of 14 questions in total, and anxiety symptoms are questioned in half of the questions and depression-related complaints in the other half.
A subscore of 8 or higher for depression or anxiety is considered a clinical case.
|
6 months
|
Pittsburgh Sleep Quality Index (PSQI)
Time Frame: 6 months
|
The questionnaire includes 21 questions covering 7 components that investigate the symptoms of sleep disturbances.
Scores range from 0 to 21 and a score of >5 is considered as a sleep disorder.
|
6 months
|
Fibromyalgia Rapid Screening Tool (FIRST).
Time Frame: 6 months
|
This scale consists of 6 questions investigating the most relevant clinical features of fibromyalgia.
The questions are answered as yes/no and 5 or more out of 6 points in total are in favor of fibromyalgia.
|
6 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Chair: Canan Sanal- Toprak, Asst.Prof, Marmara University
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Bjelland I, Dahl AA, Haug TT, Neckelmann D. The validity of the Hospital Anxiety and Depression Scale. An updated literature review. J Psychosom Res. 2002 Feb;52(2):69-77. doi: 10.1016/s0022-3999(01)00296-3.
- Mayer TG, Neblett R, Cohen H, Howard KJ, Choi YH, Williams MJ, Perez Y, Gatchel RJ. The development and psychometric validation of the central sensitization inventory. Pain Pract. 2012 Apr;12(4):276-85. doi: 10.1111/j.1533-2500.2011.00493.x. Epub 2011 Sep 27.
- Buysse DJ, Reynolds CF 3rd, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res. 1989 May;28(2):193-213. doi: 10.1016/0165-1781(89)90047-4.
- Latremoliere A, Woolf CJ. Central sensitization: a generator of pain hypersensitivity by central neural plasticity. J Pain. 2009 Sep;10(9):895-926. doi: 10.1016/j.jpain.2009.06.012.
- Lee YC, Bingham CO 3rd, Edwards RR, Marder W, Phillips K, Bolster MB, Clauw DJ, Moreland LW, Lu B, Wohlfahrt A, Zhang Z, Neogi T. Association Between Pain Sensitization and Disease Activity in Patients With Rheumatoid Arthritis: A Cross-Sectional Study. Arthritis Care Res (Hoboken). 2018 Feb;70(2):197-204. doi: 10.1002/acr.23266. Erratum In: Arthritis Care Res (Hoboken). 2020 Apr;72(4):599.
- Pinar R. Reliability and construct validity of the SF-36 in Turkish cancer patients. Qual Life Res. 2005 Feb;14(1):259-64. doi: 10.1007/s11136-004-2393-3.
- Unal-Ulutatar C, Duruoz MT. Development and validation of a quality of life scale in Familial Mediterranean Fever (FMFQoL). Mod Rheumatol. 2021 May;31(3):710-717. doi: 10.1080/14397595.2020.1775946. Epub 2020 Jun 26.
- Senerdem N, Gul A, Konice M, Aral O, Ocal L, Inanc M, Yuzbasioglu N. The use of two different Health Assessment Questionnaires in Turkish rheumatoid arthritis population and assessment of the associations with disability. Clin Rheumatol. 1999;18(1):33-7. doi: 10.1007/s100670050048.
- Familial Mediterranean fever (FMF) in Turkey: results of a nationwide multicenter study. Medicine (Baltimore). 2005 Jan;84(1):1-11. doi: 10.1097/01.md.0000152370.84628.0c.
- Ancient missense mutations in a new member of the RoRet gene family are likely to cause familial Mediterranean fever. The International FMF Consortium. Cell. 1997 Aug 22;90(4):797-807. doi: 10.1016/s0092-8674(00)80539-5.
- Silva RL, Lopes AH, Guimaraes RM, Cunha TM. CXCL1/CXCR2 signaling in pathological pain: Role in peripheral and central sensitization. Neurobiol Dis. 2017 Sep;105:109-116. doi: 10.1016/j.nbd.2017.06.001. Epub 2017 Jun 3.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
June 1, 2021
Primary Completion (Actual)
April 10, 2022
Study Completion (Actual)
August 3, 2022
Study Registration Dates
First Submitted
January 3, 2022
First Submitted That Met QC Criteria
January 3, 2022
First Posted (Actual)
January 4, 2022
Study Record Updates
Last Update Posted (Actual)
November 10, 2022
Last Update Submitted That Met QC Criteria
November 9, 2022
Last Verified
December 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 06.12.2019.1053
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Familial Mediterranean Fever
-
Rambam Health Care CampusWithdrawnFamilial Mediterranean Fever (FMF )
-
Novartis PharmaceuticalsCompletedColchicine Resistant/Intolerant Familial Mediterranean FeverIsrael
-
National Human Genome Research Institute (NHGRI)Merck Sharp & Dohme LLC; Duke University; University of Massachusetts, WorcesterRecruitingFever | Genetic Diseases | Familial Mediterranean Fever (FMF) | Autoinflammation | Periodic Fever | ROSAH | ALPK1United States
-
University of PalermoCompletedFamilial Mediterranean Fever (FMF) | Not-celiac Wheat Sensitivity (NCWS)Italy
-
University Hospital, MontpellierNot yet recruitingFamilial Mediterranean FeverFrance
-
Sohag UniversityNot yet recruitingFamilial Mediterranean FeverEgypt
-
Aristea Therapeutics, Inc.WithdrawnFamilial Mediterranean FeverIsrael, Turkey
-
University Hospital TuebingenCompleted
-
Novartis PharmaceuticalsCompletedFamilial Mediterranean FeverTurkey
-
Sheba Medical CenterUnknownFamilial Mediterranean FeverIsrael
Clinical Trials on Central Sensitization Inventory
-
Benno Rehberg-KlugCompleted
-
Caps Research NetworkCompletedCentral Nervous System SensitizationUnited States, Australia
-
Marmara UniversityCompletedInflammation | Axial Spondyloarthritis | Central SensitisationTurkey
-
Marmara UniversityRecruitingCentral SensitisationTurkey
-
KK Women's and Children's HospitalRecruitingChronic Pain | Anxiety Depression | Hysterectomy | Central SensitisationSingapore
-
SangathHarvard Medical School (HMS and HSDM); London School of Hygiene and Tropical...Completed
-
Hospices Civils de LyonUnknown
-
Marmara UniversityRecruitingFibromyalgia | Neuropathic Pain | Central SensitisationTurkey
-
Université Catholique de LouvainRecruitingSleep Quality | Gut Microbiota | Sensitization, Central | Peripheral SensitizationBelgium